NCT00679172Phase 2Completed

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

Study sponsor: Emergent BioSolutions

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2008-12Actual
Enrollment · participants187Actual
Source updated2024-04-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.